Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

INTRODUCTION: The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced NSCLC. Preclinical studies indicate that targeting CD38-positive cells with daratumumab may synergistically enhance atez...

Descripción completa

Detalles Bibliográficos
Autores principales: Pillai, Rathi N., Ramalingam, Suresh S., Thayu, Meena, Lorenzini, Patricia, Alvarez Arias, Diana A., Moy, Christopher, Hutnick, Natalie, Knoblauch, Roland, Feng, Huaibao, Kane, Colleen, Horn, Leora, Reck, Martin, Ponce, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474375/
https://www.ncbi.nlm.nih.gov/pubmed/34589982
http://dx.doi.org/10.1016/j.jtocrr.2020.100104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474375/
https://www.ncbi.nlm.nih.gov/pubmed/34589982
http://dx.doi.org/10.1016/j.jtocrr.2020.100104

Ejemplares similares